Danaher Corporation (DHR)
| Market Cap | 165.01B |
| Revenue (ttm) | 29.57B |
| Net Income (ttm) | 5.87B |
| Shares Out | 738.93M |
| EPS (ttm) | 7.93 |
| PE Ratio | 28.16 |
| Forward PE | 29.62 |
| Dividend | $1.08 (0.48%) |
| Ex-Dividend Date | Oct 11, 2023 |
| Volume | 3,543,171 |
| Open | 222.93 |
| Previous Close | 222.52 |
| Day's Range | 219.67 - 223.52 |
| 52-Week Range | 182.09 - 249.59 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 253.73 (+13.62%) |
| Earnings Date | Jan 23, 2024 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; mic... [Read more]
Financial Performance
In 2022, Danaher's revenue was $31.47 billion, an increase of 6.85% compared to the previous year's $29.45 billion. Earnings were $7.10 billion, an increase of 13.30%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $253.73, which is an increase of 13.62% from the latest price.
News
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam today announced that all Identified Clearances required in connection with the acquisition of the company by Danaher have been obtained.
Abcam shareholders approve $5.7 billion Danaher deal
Abcam shareholders on Monday approved the proposal from Danaher Corp to acquire all outstanding shares of the company for $24 per share in cash.
Shareholders of Abcam Approve Proposed Acquisition by Danaher
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Shareholders of Abcam approve proposed acquisition by Danaher.
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc (“A...
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
WASHINGTON , Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Rile...
Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.
Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...
Danaher Reports Third Quarter 2023 Results
WASHINGTON , Oct. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter ended September 29, 2023. Net earnings refer to net earnings a...
Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation's Proposed Acquisition of Abcam
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam announced that leading independent proxy advisor Glass Lewis recommended Abcam shareholders vote “FOR” Danaher's proposed acquisition of Abc...
Jonathan Milner Issues Statement Responding to the Glass Lewis Report
Jonathan Milner Issues Statement Responding to the Glass Lewis Report Welcomes the Glass Lewis report's observations on the disproportionate rewards for Abcam's Executive Directors and on the identifi...
Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation's Proposed Acquisition of Abcam
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam announced that leading independent proxy advisor ISS recommended that Abcam shareholders vote “FOR” Danaher's proposed acquisition of Abcam.
Jonathan Milner Issues Statement Responding to ISS Report
Jonathan Milner Issues Statement Responding to ISS Report Urges shareholders to disregard the ISS report and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, En...
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam filed an investor presentation on the proposed sale of Abcam to Danaher and the Independent Directors mailed a letter to shareholders.
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (Nasda...
Jonathan Milner issues Open Letter to shareholders of Abcam plc
Urges shareholders to question the scheme circular, the unacceptable Offer price and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share.
Danaher Corporation Completes Separation of Veralto Corporation
WASHINGTON , Sept. 30, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off ...
Veralto Set to Join S&P 500; Vestis to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Sept. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600 indices
Veralto stock to join S&P 500, Kohl's to join S&P SmallCap 600
Danaher Corp. DHR, -0.10% spinoff Veralto Corp. VLTO.WI, +5.02% will be added to the S&P 500 before trading Monday, when it replaces DXC Technology Co. DXC, +0.59%, which in turn will move to the S&P ...
Danaher Schedules Third Quarter 2023 Earnings Conference Call
WASHINGTON, Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023...
Danaher Lowers Price Of Tuberculosis Test After Pressure Campaign
Popular novelist and YouTuber John Green as well as international health nonprofits had been running a weeklong pressure campaign against the company.
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global ...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danahe...